R-ICE
Checked 2026-09-09
Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging
One cycle
every 14 days × 2-3 · about 4 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Rituximab Monoclonal antibody (anti-CD20, chimeric) | 375 mg/m² | IV | D1 | |
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 100 mg/m² | IV | D1-3 | |
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 5 (maximum 800 mg) | IV | D2 | |
Ifosfamide Cytotoxic chemotherapy (alkylating agent) | 5,000 mg/m² with mesna | IV | D2 (24 h infusion) |
Cycles
2-3
14-day cycle
Emetogenicity
High (>90%)
G-CSF
Built into the protocol
Notes
- ZUMA-7 and TRANSFORM: CAR-T beats salvage chemotherapy plus transplant for early relapse (within 12 months).
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
R-CHOP
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
every 21 days × 6
Pola-R-CHP
Untreated DLBCL, IPI 2-5
every 21 days × 6
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days